Flightpath Biosciences

Targeted Bacterial Deletion - in infection-associated complex disease.

[Flightpath Biosciences @FlightpathB]

https://t.co/V7o1B7uhXD

[Flightpath Biosciences @FlightpathB]

https://t.co/mbMs33AYEm

[Flightpath Biosciences @FlightpathB]

T. denticola and F. Nucleatum are known causal pathogens in periodontal disease but they can also exacerbate systemic inflammation and chronic disease. It's time to focus on them. Lets get to work!
https://t.co/j5ygLcoqns

#Forsythdentech 2023!
#Oral Health
#Dental health

[Flightpath Biosciences @FlightpathB]

Flightpath Biosciences, Inc has been selected to pitch in the Forsyth dentech Pitch Competition! We're excited for the opportunity to present our antimicrobial technology to thought leaders across the oral health innovation ecosystem. Come connect with us at #Forsythdentech 2023.

[Flightpath Biosciences @FlightpathB]

https://t.co/7f6z1xJWNH

[Flightpath Biosciences @FlightpathB]

https://t.co/nphi8eWwKK

[Flightpath Biosciences @FlightpathB]

https://t.co/sBzaYb2nNt

[Flightpath Biosciences @FlightpathB]

Why we do what we do....

[Flightpath Biosciences @FlightpathB]

https://t.co/WskhEggjme

[Flightpath Biosciences @FlightpathB]

Congratulations to the Lewis Lab at Northeastern University. This publication and this work will likely change the world for the better and alter the course of Lyme disease in a very positive way.

https://t.co/oLEekP5tER

[Flightpath Biosciences @FlightpathB]

UPDATE: We've enrolled >900 participants in largest ever clinical biomarker study of chronic LD. FP is incredibly grateful to the community w/ 200 kits completed already & eGift cards going out shortly. Stay tuned to https://t.co/TYaIsW3NuE for updates by blog!
@lymepolicywonk

[Flightpath Biosciences @FlightpathB]

UPDATE: We've enrolled >900 participants in largest ever clinical biomarker study of chronic LD. FP is incredibly grateful to the community w/ 200 kits completed already and eGift cards now en route. Stay tuned to https://t.co/PhrKLgODuA for study updates by blog! @lymepolicywonk

[Flightpath Biosciences @FlightpathB]

Flightpath Biosciences and partners at LymeDisease (dot) org and Illumina Accelerator are proud to announce the initiation of the largest clinical biomarker study ever conducted in chronic Lyme disease. Please take a look: https://t.co/RclWb6ESJl

[Flightpath Biosciences @FlightpathB]

https://t.co/qjsT77uh8d

[Illumina @illumina]

Illumina Accelerator welcomes nine exciting new #genomic startups to its second global funding cycle in the U.S. and UK. #IlluminaForStartups

https://t.co/0du0AAokiH

[Flightpath Biosciences @FlightpathB]

Big news today! Flightpath has been accepted into Illumina Accelerator's Global Class. More to come soon about our study launching March 1st - stay tuned.

https://t.co/QWDRH8Jvon

[Flightpath Biosciences @FlightpathB]

@KlausDarwin @BonnieCrater @Benioff All, more to come on this. Please stay tuned. Thank you for your support. - Flightpath Team

[Flightpath Biosciences @FlightpathB]

Congratulations to the Rajadas lab on their recent Nature publication. More evidence that Flightpath's FP-101 development candidate may be effective against multiple drug tolerant strains of Borrelia burgdorferi. We're so proud to be working on #LymeDisease #Flightpath

[Flightpath Biosciences @FlightpathB]

"Flightpath Biosciences, Inc is Selected to Participate in the Innovation Challenge at RESI Boston 2019"
https://t.co/mtc68PeXbU